WorldHeart Will Learn Fate Of Novacor As Destination Therapy Within 90 Days
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart may ask FDA's Medical Device Dispute Resolution Panel to re-evaluate the firm's PMA supplement for the Novacor left-ventricular assist device as a destination therapy, according to CEO Rod Bryden